Major Depressive Disorder - US Drug Forecast and In-Depth Industrial and Market studies Assessment to 2025

Albany, New York, Feb 02, 2017

"Major Depressive Disorder - US Drug Forecast and Market Assessment to 2025" The Report covers current Industries Trends, Worldwide Analysis, Global Forecast, Review, Share, Size, Growth, Effect.

Description-

Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. It is characterized by single or recurrent major depressive episodes (MDEs), where patients can typically experience periods of depressed mood, loss of energy, abnormal cognition, anxiety and suicidal ideation. Similar to other neuropsychiatric disorders, MDD has a multifaceted and varied etiology, and remains poorly understood. The MDD market is crowded and competitive, with more than 30 products available for the treatment of patients, the majority of which are now available as inexpensive generics. The MDD market is therefore in a dynamic phase where patent expiries for historically top-selling products such as Eli Lillys Cymbalta and Otsuka/BMS Abilify have occurred, and recent launches of Lundbeck/Takedas Trintellix and Otsuka/Lundbecks Rexulti will be a significant driver of growth in the 7MM. Growth in the MDD market is also expected to be driven by the potential introduction of six promising late-stage pipeline products into the market during the forecast period, all of which are directed towards treatment-resistant patients, a significant unmet need.

Get Sample Report With TOC @ http://www.researchmoz.us/enquiry.php?type=S&repid=943641

GlobalData estimates that the MDD market will undergo a period of steady growth from 2015 to 2025, mainly attributed to the growth in atypical antipsychotics and the expected launch of five pipeline products.GlobalData anticipates that five products in the late-stage pipeline will enter the MDD market in the US during the forecast period: Alkermes ALKS-5461, Allergan/Gedeon Richter/Mitsubishi Tanabes Vraylar, Axsome Therapeutics AXS-05, Janssens esketamine, and Allergans rapastinel.

* Scope

- Overview of MDD including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

- Detailed information on the key drugs in the US including product description, safety and efficacy profiles as well as a SWOT analysis.

- Sales forecast for the top drugs in the US from 2015-2025.

- Analysis of the impact of key events as well the drivers and restraints affecting the US MDD market.

* Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return

- Stay ahead of the competition by understanding the changing competitive landscape for MDD.

- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential

- Make more informed business decisions from insightful and in-depth analysis of drug performance

- Obtain sales forecast for drugs from 2015-2025 in the US.